Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds

Cybin (HELP) is drawing fresh attention after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%, a key marker in its broader PARADIGM program.

See our latest analysis for Cybin.

The recent APPROACH trial update comes after a sharp short term rebound in Cybin's 1 week and 1 month share price returns of 38.76% and 42.42% respectively. This is set against a year to date share price return that is still down 21.74% and a 5 year total shareholder return that has declined 91.96%, indicating improving near term momentum within a much weaker long term record for holders.

If you are looking beyond Cybin for other potential opportunities in healthcare related innovation, this could be a good moment to scan the 39 healthcare AI stocks

With Cybin shares rebounding in the short term but still carrying heavy multi year declines, current levels raise a key question for investors: is the risk already reflected in the price, or is the market quietly starting to price in future growth?

Most Popular Cybin Narrative: 16.8% Undervalued

With Cybin closing at $6.48 against a narrative fair value of $7.78, the most followed view in the market sees meaningful upside already baked into its long dated projections.

Cybin currently has no revenue. The bearish analysts are forecasting revenue to reach $5.5 million by June 2029.

The bearish analysts are not forecasting that Cybin will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Cybin's profit margin will increase from 0.0% to the average US Pharmaceuticals industry of 19.6% in 3 years.

Read the complete narrative.

Want to understand why a pre revenue company still attracts such a high implied earnings multiple in this narrative? The entire case leans on steep revenue expansion, a major swing in profit margins and a valuation framework that stretches well beyond typical pharmaceuticals assumptions. The detailed story connects these moving pieces in a way that simple price charts cannot.

Result: Fair Value of $7.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Cybin is still pre revenue and reporting quarterly net losses, and any setback in CYB003 or CYB004 trials could quickly challenge this 16.8% undervalued narrative.

Find out about the key risks to this Cybin narrative.

Next Steps

Does the mixed sentiment around Cybin leave you unsure which way to lean? Act promptly, review the data for yourself, and weigh both the potential risks and rewards via the 1 key reward and 4 important warning signs

Looking for more investment ideas beyond Cybin?

If Cybin has sharpened your focus, do not stop here. Broaden your watchlist now with a few focused stock ideas sourced from the Simply Wall St Screener.

• Spot potential value by reviewing companies highlighted in the 44 high quality undervalued stocks that combine appealing prices with stronger fundamentals.
• Strengthen your downside protection by checking out the 71 resilient stocks with low risk scores that focuses on businesses with more resilient risk profiles.
• Get ahead of the crowd by scanning the screener containing 19 high quality undiscovered gems that surfaces lesser known stocks with stronger underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com